title: [Combination Chemotherapy Using Oxaliplatin plus S-1 for Well-Advanced Gastric Cancer].
abstract: We studied the clinical efficacy of pre-operative combination chemotherapy using S-1 plus oxaliplatin for advanced gastric cancer. Four patients hadclinical Stage IV disease, 1 patient had clinical Stage III C disease, 2 patients had clinical Stage III B disease, and 1 patient had clinical Stage III A disease. The patients received 2-8 courses of oxaliplatin(130mg/m2)on day 1, andS -1 on days 1-14 every 3 weeks. The response rate was 56%(5 PR, 1 PD, and2 SD), andthe disease control rate was 88%. Toxicities were Grade 2 anemia, Grade 1 peripheral neuropathy, Grade 1 fatigue, and anorexia. Five of the 8 patients underwent R0 surgery after SOX chemotherapy, and no severe complications occurred. Histological responses were Grade 3 for 2 cases, Grade 2 for 2 cases, andGrad e 1a for 1 case. The SOX regimen showeda high objective tumor response, andis one of the promising regimens in the neoadjuvant setting for well-advanced gastric cancer.
authors.affiliation: Dept. of Surgery, National Hospital Organization Disaster Medical Center.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Saito
authors.forename: Yuki
authors.initials: Y
authors.lastname: Suematsu
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Yamagishi
authors.forename: Miyuki
authors.initials: M
authors.lastname: Takahashi
authors.forename: Mao
authors.initials: M
authors.lastname: Nakayama
authors.forename: Michiko
authors.initials: M
authors.lastname: Fukabori
authors.forename: Akihiko
authors.initials: A
authors.lastname: Morita
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Wakabayashi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Itoh
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid